IL-2 immunotherapy expands tumor-infiltrating DCs through a lymphoid pathway, favoring the conversion of poorly immunogenic into immunogenic tumors. This material relates to a paper that appeared in the Sep. 16, 2020, issue of Science Translational Medicine, published by AAAS. The paper, by M.E. Raeber at University Hospital Zurich in Zurich, Switzerland; and colleagues was titled, "Interleukin-2 signals converge in a lymphoid-dendritic cell pathway that promotes anticancer immunity."
Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact Science for permission.